MedPath

Cannabidiol for At Risk for psychosis Youth

Phase 3
Recruiting
Conditions
ltra-High Risk of Psychosis
Ultra-High Risk of Psychosis
Mental Health - Psychosis and personality disorders
Registration Number
ACTRN12621000349842
Lead Sponsor
Orygen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
405
Inclusion Criteria

1.Aged 12-25 years (inclusive) at entry;
2.Sufficient fluency in English (for assessment purposes);
3.Ability to provide informed consent (parental/guardian consent will be obtained for participants aged <18 years);
4.Meeting one or more UHR for psychosis groups as defined in Table 1 of the study protocol; and
5.Attenuated psychotic symptoms present in the past month at UHR level as defined in Table 1 of the study protool.

Exclusion Criteria

1.Ultra-High Risk symptoms only present during acute intoxication
2.If prescribed psychotropic medication (e.g. antidepressant medication) the individual must have been on a stable dose for a minimum of 6 weeks prior to randomisation). Antipsychotic medication is not an exclusion criterion. In the case of current antipsychotic use, medication will be tapered and ceased at entry to the study.
3.Pregnancy, lactation, or if sexually active, no effective contraception (applies to both male and female participants)
4.Clinical blood test findings that might compromise participant safety or confound the trial results
5.Acute or unstable systemic medical disorder
6.Psychiatric condition due to a medical condition;
7.Severe disturbance, such that the person is unable to comply with either the requirements of informed consent or the treatment protocol
8.Current acute suicidality/self- harm or aggression/dangerous behaviour
7. Diagnosis of a serious developmental disorder or a documented history of developmental delay or intellectual disability
9.History of a psychotic episode of one week or longer

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath